Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia

Cancer Chemother Pharmacol. 1989:24 Suppl 1:S16-9. doi: 10.1007/BF00253232.

Abstract

Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P less than 0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Diseases / drug therapy*
  • Bone Marrow Diseases / mortality
  • Bone Marrow Transplantation
  • Child
  • Combined Modality Therapy
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Random Allocation
  • Recurrence
  • Remission Induction
  • Time Factors